Navigation Links
FTC Study Finds that in FY 2011, Pharmaceutical Industry Continued to Make Numerous Business Deals that Delay Consumers' Access to Lower-Cost Generic Drugs
Date:10/25/2011

tudy has found that patent settlements that include a payment or other compensation delay generic entry on average by 17 months longer than those that do not include a payment.  According to the Congressional Budget Office, proposed legislation would reduce the federal deficit by $2.67 billion over 10 years.

The FTC has challenged a number of these patent settlement agreements in court, contending that they are anticompetitive and violate U.S. antitrust laws.  The agency also has supported legislation in Congress that would prohibit pay-for-delay settlements that increase the cost of prescription drugs.

According to the new staff report, companies reached a total of 156 final patent settlements in FY 2011.  Twenty-eight settlements contained a payment to a generic manufacturer and also restricted the generic's ability to market its product.  Of those 28 settlements, 18 involved generics that were so-called "first filers," meaning that they were the first to seek FDA approval to market a generic version of the branded drug, and, at the time of the settlement, were eligible to exclusively market the generic product for a period of time.  Because of the regulatory framework, when first filers delay entering the market, other generic manufacturers can also be blocked from entering the market, which makes such patent settlement deals particularly harmful to consumers.

The report summarizes data on patent settlements filed with the FTC and the Department of Justice during FY 2011 under the Medicare Modernization Act of 2003.

The FTC's Bureau of Competition works with the Bureau of Economics to investigate alleged anticompetitive business practices and, when appropriate, recommends that the Commission take law enforcement action.  To inform the Bureau about particular business practices, call 202-326-3300, send an e-mail to antitrust{at}ftc{dot}gov, or write to the Office of Policy and Coordination, Bureau of
'/>"/>

SOURCE Federal Trade Commission
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... -- Research and Markets  has announced the addition ... & Technologies" report to their offering. ... or you wish to expand your product line, you,ll ... The authors know you want to make effective product ... generate improved revenues and take market share from your ...
(Date:8/22/2014)... 22, 2014   Zacks Equity Research highlights Epizyme (Nasdaq: ... Day and Panera (Nasdaq: PNRA - Free Report ) as ... analysis on Amicus Therapeutics (Nasdaq: FOLD - Free Report ), ... SHPG - Free Report ). Here is a ... the Day : The biotech bull market is ...
(Date:8/22/2014)... DUBLIN , August 22, 2014 ... of Hospital TVs Today Lincor announced general ... Patient Engagement solution that delivers a range of education, ... sets.      (Logo: http://photos.prnewswire.com/prnh/20140822/702945) , ... in defining point of care patient engagement to bedside ...
Breaking Medicine Technology:Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 2Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 4Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 5Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 6Lincor Unveils Next Generation TV-based Patient Engagement Solution 2
... Medical Imaging (RMI) in Flint announced today that it is ... Breast Magnetic Resonance Imaging (MRI) by the American College of ... the Breast MRI Accreditation Program to recognize imaging ... for Breast MRI. RMI received this new distinction after a ...
... Pharmaceuticals, Inc. (Nasdaq: ARNA ) announced today ... trial program for APD597 (JNJ-38431055) under its collaboration with ... APD597 and has notified Arena that it is terminating ... GPR119 agonist intended for the treatment of type 2 ...
Cached Medicine Technology:Exciting Healthcare News for Women of Mid Michigan 2Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes 2Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes 3Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes 4Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes 5
(Date:8/22/2014)... Americans know little about how Ebola is transmitted and harbor ... United States, a new survey shows. About four in ... a major Ebola outbreak in the United States, and one-quarter ... get sick with the deadly virus in the next year, ... However, those opinions don,t match reality, the Harvard researchers ...
(Date:8/22/2014)... Mi40x , the latest guide from ... people how they can use a simple 4-minute trick to ... of weeks has caught the attention of Shane Michaels, prompting ... the most well-known bodybuilders in the industry, and if he ... that in itself is a testament to how effective this ...
(Date:8/22/2014)... 2014 Paying tuition and other related ... coming year for four nurse educators pursuing advanced degrees, ... for Nursing Foundation for Nursing Education . This year’s ... $10,000 more than in 2013, thanks to these named ... Elizabeth Isaac Marcil Endowment Funds, both donated by Kathy ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Mueller Sports ... Plantar Fasciitis, an exciting new product that provides non-drug ... to stay active while you heal. The package includes ... truly a new technology – it is not kinesiology ... FasciaDerm® PFTape™ System for Plantar Fasciitis is ...
(Date:8/22/2014)... NJ. August 22, 2014. A new study ... persons with multiple sclerosis (MS) may be able ... The study was epublished ahead of print on ... Helen Genova, Hali Griswold, Nancy D. Chiaravalloti & ... persons with multiple sclerosis doi: 10.3233/NRE-141113). Self-awareness is ...
Breaking Medicine News(10 mins):Health News:Many Americans Harbor Unfounded Fears About Ebola Outbreak: Survey 2Health News:Mi40x: Review Exposes Ben Pakulski’s Guide to Packing on Lean Muscle Fast 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 3Health News:Mueller Introduces FasciaDerm® PFTape™ System for Plantar Fasciitis 2Health News:Kessler Foundation study of self-awareness in MS has implications for rehabilitation 2
... for most commonly used infection-fighters, , MONDAY, Nov. 2 ... raise the risk for most birth defects, though there ... which is the most commonly used antibiotic during pregnancy, ... widely prescribed antibiotics, were not associated with increased risk ...
... TO CORRESPONDENTS , SILVER SPRING, Md., Nov. 2 ... released a listing of eight recent consumer health information ... can be accessed from the agency,s Web page for ... sign-up for e-mail notices of new consumer updates on ...
... , , Highest Levels of BPA Were Detected in ... Dietary Exposure Could Approach Levels Shown to Cause Harm in Animal ... , YONKERS, N.Y., Nov. 2 Consumer Reports, latest tests ... found that almost all of the 19 name-brand foods tested contain ...
... Infants born to women who received influenza vaccine during ... born to unvaccinated mothers, according to preliminary results of ... Medicine. The team presented the study October 29 at ... of America in Philadelphia. Influenza is a ...
... the 2010 Medicare Physician Fee Schedule will restrict life-saving ... wait times to receive care, and cause life threatening ... serious illnesses. "These short sighted, unfounded and ... to cutting-edge imaging scans, and delay diagnosis of cancers ...
... study finds, , MONDAY, Nov. 2 (HealthDay News) -- ... linked to aggression in young children. , This research, ... of Pediatrics & Adolescent Medicine , found that direct ... viewing in the household were both associated with increased ...
Cached Medicine News:Health News:CDC Study Links 2 Antibiotics to Birth Defects 2Health News:CDC Study Links 2 Antibiotics to Birth Defects 3Health News:CDC Study Links 2 Antibiotics to Birth Defects 4Health News:FDA CONSUMER HEALTH INFORMATION UPDATES: Fraudulent H1N1 flu products, hearing aids, sound amplifiers, tobacco regulation, FDA's international posts, LASIK eye surgery, and FDA MedWatch safety alerts 2Health News:FDA CONSUMER HEALTH INFORMATION UPDATES: Fraudulent H1N1 flu products, hearing aids, sound amplifiers, tobacco regulation, FDA's international posts, LASIK eye surgery, and FDA MedWatch safety alerts 3Health News:Consumer Reports: Tests Find Wide Range of Bisphenol A in Canned Soups, Juice, and More 2Health News:Consumer Reports: Tests Find Wide Range of Bisphenol A in Canned Soups, Juice, and More 3Health News:Consumer Reports: Tests Find Wide Range of Bisphenol A in Canned Soups, Juice, and More 4Health News:Consumer Reports: Tests Find Wide Range of Bisphenol A in Canned Soups, Juice, and More 5Health News:Flu vaccine given to women during pregnancy keeps infants out of the hospital 2Health News:Imaging cuts in Medicare fee schedule: An access catastrophe and danger to patients 2Health News:Imaging cuts in Medicare fee schedule: An access catastrophe and danger to patients 3Health News:TV May Increase Aggression in Toddlers 2Health News:TV May Increase Aggression in Toddlers 3
Reusable shielded cable...
... The STREP A OIA MAX test ... of Group A Strep with a simple, ... minutes. This combination of performance, speed, and ... care while reducing overall costs for diagnosing ...
The GC OIA test is a rapid assay for the diagnosis of gonorrhea. Thermo solved the challenge of developing a specific rapid assay for Neisseria gonorrhea by using the proprietary ribosomal protein, ...
... a high performance assay for the undifferentiated ... with a simple, easy-to-use test that provides ... Assay advantages include superior performance with mucoid ... 14-day viral culture enables you to decrease ...
Medicine Products: